GANX Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 mai 2024 @ 22:00):

Stats
Dagens volum	57 765.00
Gjennomsnittsvolum	160 995
Markedsverdi	48.17M
EPS	$0 ( 2024-03-28 )
Neste inntjeningsdato	( $-0.300 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.740
ATR14	$0.0160 (0.55%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Mack Gene	Buy	200 000	Employee Stock Option (right to buy)
2024-04-05	Mack Gene	Buy	0
2024-03-28	Riley Jeffrey Scott	Buy	30 000	Common Stock
2024-03-26	Alder Matthias	Sell	18 750	Restricted Stock Units
2024-03-26	Alder Matthias	Buy	637	Common Stock

INSIDER POWER
86.81
Last 62 transactions
Buy: 1 996 906 \| Sell: 408 942

Volum Korrelasjon

Lang: 0.05 (neutral)

Kort: -0.61 (weak negative)

Signal:(30.46) Neutral

Gain Therapeutics, Inc. Korrelasjon

10 Mest positive korrelasjoner
EMLD	0.95
ARRW	0.946
FTAA	0.937
OXAC	0.934
BCOR	0.933
HCVI	0.933
ARDX	0.932
MSAC	0.931
ADAL	0.93
FWAC	0.93

10 Mest negative korrelasjoner
BFC	-0.941
VORB	-0.926
BMRA	-0.923
ZSAN	-0.922
ORPH	-0.922
YJ	-0.92
EVLO	-0.92
CUTR	-0.919
HALO	-0.919
GRIN	-0.919

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Gain Therapeutics, Inc. Korrelasjon - Valuta/Råvare

0.47
( neutral )

0.29
( neutral )

0.00
( neutral )

0.15
( neutral )

-0.60
( weak negative )

Gain Therapeutics, Inc. Økonomi

Annual	2023
Omsetning:	$55 180.00
Bruttogevinst:	$-25 202.00 (-45.67 %)
EPS:	$-1.710

FY	2023
Omsetning:	$55 180.00
Bruttogevinst:	$-25 202.00 (-45.67 %)
EPS:	$-1.710

FY	2022
Omsetning:	$140 108
Bruttogevinst:	$75 940.00 (54.20 %)
EPS:	$-1.480

FY	2021
Omsetning:	$164 994
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-2.37

Financial Reports:

No articles found.

Gain Therapeutics, Inc.

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.